Cover Image

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Mature T-cell and natural killer (NK)–cell lymphomas are rare and heterogeneous diseases following an aggressive clinical course which necessitates immediate therapy. Outcome is generally believed poor although only 1 recent study1 comprises all major T-cell lymphoma subtypes according to the World...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmitz, Norbert (Author) , Trümper, Lorenz (Author) , Ziepert, Marita (Author) , Nickelsen, Maike (Author) , Ho, Anthony Dick (Author) , Metzner, Bernd (Author) , Peter, Norma (Author) , Loeffler, Markus (Author) , Rosenwald, Andreas (Author) , Pfreundschuh, Michael (Author)
Format: Article (Journal)
Language:English
Published: July 21, 2010
In: Blood
Year: 2010, Volume: 116, Issue: 18, Pages: 3418-3425
ISSN:1528-0020
DOI:10.1182/blood-2010-02-270785
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2010-02-270785
Verlag, lizenzpflichtig, Volltext: https://ashpublications.org/blood/article/116/18/3418/27966/Treatment-and-prognosis-of-mature-T-cell-and-NK
Get full text
Author Notes:Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Maike Nickelsen, Anthony D. Ho, Bernd Metzner, Norma Peter, Markus Loeffler, Andreas Rosenwald, and Michael Pfreundschuh
Description
Summary:Mature T-cell and natural killer (NK)–cell lymphomas are rare and heterogeneous diseases following an aggressive clinical course which necessitates immediate therapy. Outcome is generally believed poor although only 1 recent study1 comprises all major T-cell lymphoma subtypes according to the World Health Organization classification2,3 with spin-off studies reporting on clinical outcome and prognostic factors of various subtypes. In contrast to the progress made in the treatment of aggressive B-cell lymphoma, evidence for similar therapeutic improvements in T- and NK-cell lymphoma is largely absent. Therefore, we analyzed a large cohort of patients with T-cell lymphoma who have been treated on protocols of the German High-Grade Non-Hodgkin Lymphoma Study Group (Deutsche Studiengruppe Hochmaligne Non-Hodgkin Lymphome [DSHNHL]). We were particularly interested in the long-term results achieved with “standard” CHOP (cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone/prednisolone) and CHOP-like therapy and wanted to define prognostic factors which should influence the decision which patients should be treated on standard or experimental protocols in the future.
Item Description:Gesehen am 20.06.2023
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2010-02-270785

Similar Items